Original Research Article

Renin angiotensin system and pulmonary hemodynamics in chronic obstructive pulmonary disease

Preeti Chauhan¹, Rajesh Chetiwal²

¹Department of Biochemistry, Lady Harding Medical College, New Delhi, India
²Department of Medicine, ESI PGIMSR, Basaidarapur, New Delhi, India

Received: 03 January 2018
Accepted: 03 February 2018

*Correspondence:
Dr. Rajesh Chetiwal
E-mail: dr.chetiwal@gmail.com

ABSTRACT

Background: Pulmonary hypertension in chronic obstructive pulmonary disease (COPD) due to chronic alveolar hypoxia is probably the main contributor to the pathogenesis of pulmonary hypertension in COPD. Angiotensin II is a potent vasoconstrictor in renin angiotensin aldosterone system (RAAS), it has been shown to promote growth response in vascular smooth muscle cell contributing towards pulmonary hypertension. So, the Echocardiographically measured MPAP and its correlation with RAAS in patients of COPD was evaluated.

Methods: A prospective observational study was done in 32 patients with COPD and 10 age matched healthy, non-smoker subject included as controls. Stable patients requiring no change in their medication in the previous four weeks and not having had an acute exacerbation in that period were included. MPAP was calculated. Measurement of Ang II and aldosterone was done.

Results: Thirty-two cases of COPD, meeting inclusion criteria were enrolled comprising of 32 males and the mean age of patients ±2sd was (55.6 ±16.8), while mean age of controls ± 2sd was 49.60 ±5.56. Arterial blood gas analysis, PaO₂ ranged from (mean±2sd 75.44±12.1), PaCO₂ ranged from (mean ±2sd 41.36±3.79) and SpO₂ ranged from (mean±2sd 94.03 2±.74). Mean ±2sd of plasma Ang II in COPD cases was (4.9±3.8) ng/dl, significantly higher in comparison with controls (p < 0.001). Mean ±2sd of plasma ACE activity was (51.12±26.9) in COPD. Mean ±2sd of plasma aldosterone was (182.35±364.2) in COPD cases with significant (p<0.01). The MPAP in COPD cases was (mean±2sd 34.53±7.70).

Conclusions: Use of Doppler has the advantage of being noninvasive and has been shown to be extremely reproducible in evaluation of MPAP and CO. The increased level of Ang II with increase MPAP in the present study would suggest that this may be a suitable model for investigating effects of novel vasodilator drugs for the treatment of pulmonary hypertension developed due to COPD.

Keywords: Aldosterone, Angiotensin, COPD, Pulmonary hypertension, Renin

INTRODUCTION

Pulmonary hypertension is the main cardiovascular complication of chronic obstructive pulmonary disease (COPD), it is associated with substantial increase in morbidity and mortality. Structural remodeling of the pulmonary vasculature as a consequence of chronic alveolar hypoxia is probably the main contributor to the pathogenesis of pulmonary hypertension in COPD. Other factors may be involved including hyperinflation and loss of alveolar capillaries in emphysema. Hypoxia and Hypercapnia both increases pulmonary vasculature and induces pulmonary hypertension (PH). Long term oxygen therapy improves survival but does not revise the
 pulmonarvasculaturechanges. Thereisimbalancein
vasoactivefactorsandthedefinite roleofthesese
vasoactivefactorsinPHhasbeenstudied, the
biochemicalandhormonalmediatorsofhypoxiainduces
PHarepoorlydefined.

AngiotensinII(Ang.II)isapotentvasoconstrictorandin
COPDthereisactivationofreninangiotensinaldosterone
system (RAAS). Direct elevation of Ang. II and
Angiotensinconverting enzyme (ACE) activity in
relationtothemeanpulmonaryarterial pressurehasnotbeen
explored. Indeed Ang. II has been shown to promote
growth response in vascular smooth muscle cell. So
Ang. II could contribute directly to vascular remodeling.

Therefore, the present study has been carried out to
evaluate the role of RAAS in patients of COPD and
abnormalities of Arterial blood gas (ABG) in relationship
with the echocardiographically measured MPAP. Moreover, pulmonary artery pressure rises markedly in
COPD patients on minimal exertion and it is likely that
pulmonary hypertension contributes partly to exercise
limitation in these patients. The aims and objectives of
the present study were to evaluate and analyze abnormal
Arterial blood gas (ABG) and its correlation with the
echocardiographically measured MPAP and the role of
RAAS in patients of COPD.

METHODS

A Prospective observational study was done in 32 male
COPD patients in the outpatients setting in a teaching
institute, New Delhi. Ten age matched healthy,
nonsmokersubjectincluded as controls. The study was
approved by the institutional review committee and an
informed consent was taken.

The diagnosis of COPD was based on the criteria of
British thoracic society and established by history of
smokinggreaterthan20 packyears,coughwith
expectorationaccompanied by progressively increasing
dyspnoea on exertion. Patients of asthma were excluded
from the study. Only stable patients requiring no change
in their medication in the previous four weeks and not
having had an acute exacerbation in that period were
included.

The inclusion criteria included an FEV1/FVC ratio of less
than 70% and a post dilator increase in FEV1 of less than
12% and 200ml from the initial value. Patients with
clinical cor pulmonale, congenital, rheumatic or any
valvular heart disease, systemic hypertension, coronary
artery disease and any other past or concurrent pulmonary
disease, diabetes mellitus, renal failure, carcinoma,
connectivetissue disorder and liver disease were
excluded clinically and on the basis of biochemical test
where relevant. None of the patients consumed alcohol
on regular basis or had any dietary deficiency of vitamins
(B group) or had any disease such as malabsorption that
could cause vitamin deficiency. These patients were not
on any medication other than that required for COPD.
These drugs included inhaled bronchodilator (salbutamol
and ipratropium bromide) and corticosteroids
(budesonide, beclimethasone or fluticasone)

The investigations were carried out in the morning
between 10am to 12 noon. The patients were asked not to
take bronchodilator 12 hour before the tests. Inhaled
corticosteroids were allowed in the same dosage as being
already taken. A light dinner was permitted at least 12
hours before the test. Spirometry was performed on dry,
rolling - seal spirometer of the Transfer test C model lung
function machine (P.K.Morgan, Kent, UK).

Maximal expiratory flow volume (MEFV) curves were
obtained. Three acceptable and at least two reproducible
curves were obtained in each subject. The highest FEVI
obtained were recorded. Reference equations for north
Indian adults were used to calculate the percentage-
predicted values. Arterial blood gas analysis was carried
out on a sample drawn from the radial artery in a
heparinized glass syringe and measured in
instrumentation ABG machine (model 1312).

Echocardiographic assesement was done by using all
standard echocardiographic windows (parasternal long
axis view, parasternal short axis view, apical four
chamber view, subcostal view). Following M-mode and
2D assesment of morphology, color flow mapping was
done to identify the pulmonary and tricuspid regurgitant
jets. A pulsed doppler study was next applied confirn
and localize the above regugitant jets and then continous
wave doppler study was done to record their maximal
velocity. MPAP was calculated from the right ventricular
outflow tract acceleration time using Mahan’s equation.

Measurement of Ang. II and aldosterone was done in 10
ml venous sample collected in chilled tube containing
EDTA (12.5mmol/l) and o-phenanroline (2.6mmol/l). It
was placed immediately on ice, centrifuged at 4ºC at
approximately 6000 rpm for 4 minutes and plasma was
stored in aliquotes at -80ºC till the time of measurement,
5ml venous sample was also collected at the same time
for measurement of angiotensin converting enzyme
activity in tubes containing Acid citrate dextrose (ACD)
(1%). It was centrifuged at 37º C at 3000rpm for 10
minutes and plasma was stored at -80ºC.

Procedure

By ELISA kit (Peninsuala Laboratories, USA) measured
plasma ANG II level. Ang. II was extracted from plasma
on C 18 sep columns by using 1% trifluoroacetic acid
(TFA) in 95% distilled water and 60% acetonitrile in 1%
TFA in 39% distilled water. The eluent was evaporated to
dryness by lyophilisation and dried extract was stored at
- 200ºC. The assay of Ang. II resides in the competition
between biotinylated peptide for antibody binding site
with the standard peptide and the sampled Ang. II.
Separation of bound antibody from free fraction is
achieved by washing and SA-HRP, TMB is allowed to react with the bound HRP. The color intensity depends on quantity of biotinylated peptide bound to immobilized antibody. The minimum detectable range for kit was .02-.04 ng/ml, the range of the kit was 0-20ng/ml and it has 100% cross reactivity with Ang. II (human), val 5 Ang II (human) and 0.9% with renin substrate. Plasma aldosterone was measured by Radioimmunoassay (immunotech, France) and expressed as pg/ml. aldosterone assay was performed using a radio immunologic method based on a polyclonal antibody and a radio iodinated tracer.

The technique proposed involves the separation of the free fraction and it has 100% cross reactivity with aldosterone and .002% with 18 OH-corticosteroid. Within assay and between assay variability was 8.2% and 14%.

The ACE activity was measured spectrophotometrical method of Buttery et al using the synthetic substrate, N-[(2-furlyl)acryloly]–L-phenylalanylglycylglycine (FAPGG) (SIGMA). The ACE activity was measured in U/L.11

RESULTS

Thirty-two cases of COPD, meeting inclusion criteria were enrolled comprising of 32 males and the majority of the patients were in age group ranged from 32 to 72 years mean±2sd (55.6±16.8). The age of controls ranged from 38 to 56 years old. The mean±2sd 49.60±5.56. All the controls were nonsmoker and in COPD pack years of smoking is (mean ±2sd 46±4.43) years. Seven patients were classified having stage II COPD and eight patients were in stage III and two patients were in stage I COPD (Table 1).

Table 1: Age sex distribution.

| Characteristic       | Control N=10 | COPD N=32 |
|----------------------|--------------|-----------|
| Age (in years)       | 49.60±5.56   | 55.6±16.8 |
| Sex                  |              |           |
| Male                 | 9            | 32        |
| female               | 1            |           |
| Duration of smoking  | No history of smoking | 27.5±9.16 |
| No of cigarettes     | ---          | 31.2±10.66 |
| Pack year of smoking | ---          | 41.6±18.48 |

Expressed as mean ± 2standard error

Table 2: ABG analysis

| Abg     | Range | Cpd patients |
|---------|-------|--------------|
| pH      | 7.30-7.49 | 7.30±5.35 |
| PaO2    | 71.0-80.23 | 75.44±12.1 |
| PaCO2   | 39.5-43.6 | 41.36±3.79 |
| HCO3    | 22.7-26.9  | 25.25±2.7  |
| SPO2    | 88.2-96.5  | 94.03±0.74 |

Expressed as mean±2standard error

Arterial blood gas analysis, PaO2 was (mean±2sd 75.44±12.1), PaCO2 was (mean±2sd 41.36±3.79) and SpO2 was (mean±2sd 94.03 2±0.74). Bicarbonates were (mean±2sd 25.25±2.7) (Table 2).

In the controls mean ±2sd of plasma Ang. II was (0.37±0.30) while in COPD it was (4.9±3.8) ng/dl. The plasma Ang. II level in control and cases compared by student t test showed that plasma Ang. II level were significantly (p < 0.001) higher in COPD cases (Table 3).

Table 3: ACE, Aldosterone and Ang II.

| Components | Control N=10 | COPD N=32 | P value |
|------------|--------------|-----------|---------|
| Ace activity | 41.2±15.22  | 51.12±26.9| <0.01   |
| Aldosterone | 57.24±18.99 | 182.35±364.2| <0.01   |
| Ang. II     | 0.37±0.3    | 4.9±3.8   | <0.001  |

P<0.01 significant

Table 4: Correlation between MPAP and plasma Ang II, ACE Activity and Aldosterone in patients.

| COPD N=32 | R (Spearman’s coefficient of correlation) | P     |
|----------|------------------------------------------|-------|
| Ang II   | 0.55                                     | <0.01 |
| ACE Activity | 0.14                                      | ns    |
| Aldosterone | 0.26                                      | ns    |

P<0.01 significant, ns is not significant

In the controls mean ±2sd of plasma ACE activity was (41.2±15.22) while in COPD it was (51.12±26.9). The plasma ACE activity showed not much difference but, in some cases, it was disproportionately high. In the controls mean ±2sd of plasma aldosterone was (57.24±18.99) while in COPD cases it was (182.35±364.2). The plasma level of aldosterone as compared by student t showed (p<0.01). The MPAP in COPD cases was (mean±2sd 34.53±7.70) (Table 4).

DISCUSSION

The result of the present study showed that there is direct correlation of Ang. II with MPAP in stable patients of COPD. This suggests that the elevated levels of Ang. II in cor pulmonale, along with hypoxemia may be involved in pathophysiology of raised peripheral vascular resistance. In our study we have not found direct correlation of Ang. II with PaO2 and SpO2. It is also in contrast of studies which show the direct presser effect of Ang. II also facilitate the vasoconstrictor response to hypoxemia as suggested by animal studies.12-14 However, hypoxemia need not be present at all the time. Even transient or shortterm hypoxia as can occur during exercise, acute exacerbation or in sleep may be sufficient to cause increase in MPAP and can cause pulmonary hypertension. In another study PaO2 and PaCO2 was not found to correlate with MPAP as measured by cardiac catheter (wright). The pulmonary vasculature has an inherently lower resistance as compared to systemic
circulation. So Ang. II has greater response in pulmonary circulation. So, a lower level of basal vascular tone in pulmonary circulation produces more presser effect of Ang. II on infusion in men and their might be the possibility that the pulmonary vascular response as measured as MPAP in our patient might be attenuated either because of raised basal level of vascular tone or as a consequence of tachyphylaxis due to persistently high level of Ang. II found in COPD patients. So, the MPAP measured in COPD may not be giving us clear picture of pathophysiological changes occurring in Cor Pulmonale.

Although patients were clinically stable, in most of them there was a disproportionate increase in the ACE activity. Since ACE is primarily membrane bound enzyme plasma ACE activity may not accurately reflect the in vivo conversion rate of Ang. I to Ang. II. Variation in ACE activity is known to exist in the population as the result of insertion/deletion polymorphism of ACE gene.

In another study in chronic stable COPD patients elevated ACE activity was observed raising the possibility that in this condition different isoenzymes with higher specific activity might be released. In the setting of cor pulmonale, role of drugs such as ACE inhibitors have been studied. There is however conflicting evidence in the literature regarding their role in reduction of MPAP and CO. Use of Echodoppler to measure MPAP and Cardiac output (CO), Doppler has the advantage of being noninvasive and has been shown to be extremely reproducible in evaluation of MPAP and CO. The increased level of Ang. II with increase MPAP in the present study would suggest that this may be a suitable model for investigating effects of novel vasodilator drugs for the treatment of pulmonary hypertension developed due to COPD.

Our finding of raised MPAP in these patients is also in favor of not finding correlation with ACE activity. Plasma Aldosterone level increases in COPD when hypoxia and hypercapnia are present. In our patients also increase in aldosterone was found as compared to controls although the difference was significant. It was not correlated with high MPAP.

CONCLUSION

Use of Echodoppler to measure MPAP and Cardiac output (CO), Doppler has the advantage of being noninvasive and has been shown to be extremely reproducible in evaluation of MPAP and CO. The increased level of Ang. II with increase MPAP in the present study would suggest that this may be a suitable model for investigating effects of novel vasodilator drugs for the treatment of pulmonary hypertension developed due to COPD.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** The study was approved by the institutional ethics committee

**REFERENCES**

1. Cooper R, Ghali J, Simmons BE, Castaner A. Elevated pulmonary artery pressure. An independent predictor of mortality. Chest 1991;99(1):112-20.
2. Pride NB, Burrows B. Development of impaired lung function. Natural history and risk factors. In chronic obstructive pulmonary disease. Springer, Boston;1996:69-91
3. Weitznblum E, Chaouat A, Oswald MS. Pulmonary hypertension due to chronic hypoxic lung disease. In pulmonary circulation.1996;156-70.
4. Heath D. Remodelling of the pulmonary vasculature in hypoxic lung disease. In pulmonary circulation.1996;171-9.
5. Burrows B, Kettel LJ, Niden AH, Rabinowitz M, Diener CF. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med. 1972;286(17):912-8.
6. Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implication for treatment. Thorax. 2005;60:605-9.
7. Wilkinson M, Langhorne CA, Heath D, Barer GR, Howard P. A pathophysiological study of 10 cases of hypoxic cor pulmonale. QJM: Int J Med. 1988 Jan;66(1):65-85.
8. Morell NW, Morris KG, Stenmark KR. Role of angiotensin converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol. 1995;269:H1186-1194.
9. lipworth BJ, Dagg KD. Vasocostriction effects of Angiotensin II on the pulmonary vascular bed. Chest. 1994;105:1360-4.
10. Fernandez LA, Twicker J, Meal A. Neovascularization produced by Angiotensin II. J Lab Clin Med. 1985;105:141-6.
11. Buttery JE, Stuart S. Assessment and optimization of kinetic methods for Angiotensin – converting enzyme in plasma. Clin Chem. 1993;39:312-6.
12. Berkov S. Hypoxic pulmonary vasoconstriction in the rat: the necessary role of Angiotensin II. Circ Res. 1974;35:256-61.
13. Zakheim RM, Mattioli L, Molteni A, Mullis KB, Bartley J. Prevention of pulmonary vascular changes of chronic alveolar hypoxia by inhibition of Angiotensin I converting enzyme in rat. Lab Invest. 1975;35:57-61.
14. Ives H, Benoit R, Francois K, Dominique B, Guiti Malekzadeh M et al. Endogenous angitensin II in the regulation of hypoxic pulmonary vasoconstriction in anesthetized dogs. Crit Care 2004;8:R163-R171.
15. Motwani JG, Struthers AD. Dose response study on the redistribution of intravascular volume by Angiotensin II in man. Clin Sci. 1992;82:397-405.
16. lipworth Brian J, Dagg Kenneth D. Vasocostrictor effects of Angiotensin II on the pulmonary vascular bed. Chest. 1994;105:1360-9.
17. Ryan US, Ryan JW, Whitaker C, Chiu A. Localization of Angiotensin converting enzyme (kininase II): Immunocytochemistry and immuno-fluorescence. Tissue Cell. 1976;7:125-45.
18. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corrol P and Soubrier F. An insertion/deletion polymorphism in the Angiotensin converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343-6.
19. Edmund AW, Wulfie friedlander Eric D, Bateman, Kirch RE. Serum Angiotensin converting enzyme activity concentration and specific activity in granulomatous interstitial lung disease, Tuberculosis and COPD. Chest. 1995;107:706-10.
20. Cargill RI, Lipworth BJ. Lisinopril attenuates acute hypoxic pulmonary vasoconstrictions in humans. Chest 1996;109:424-29.
21. Prewitt RL, Leffler CW. Feline hypoxic pulmonary vasoconstriction is not blocked by angiotensin I converting enzyme inhibitor captopril. J Cardivas Pharmacol 1981;3:293-98.
22. Pison CM, Nolf JE, Levy PA, Dubois F, Brambilla CG, Paramella B. Effect of captopril combined with oxygen therapy at rest and on exercise in patients with chronic bronchitis and pulmonary hypertension. Respiration. 1991;58(1):9-14.
23. Zielinski J, Hawrylikiewicz I, Gorecka D, Głuskowski J, Koscinska M. Captopril effects on pulmonary and systemic hemodynamics in chronic cor pulmonale. Chest. 1986;90(4):562-5.
24. Nong Z, Stassen JM, Moons L, Collen D, Janssens S. Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodelling. Circulation. 1996;94(8):1941-7.
25. Patakas D, Georgopoulos D, Rodini H, Christaki P. Effects of captopril in patients with chronic obstructive pulmonary disease and secondary pulmonary hypertension. Postgrad Med J. 1988;64(749):193-5.
26. Laaban JP, Diebold B, Zellinski R, Lafay M, Raffoul H, Rochemaure J. Noninvasive estimation of systolic pulmonary artery pressure using Doppler echocardiography in patients with chronic obstructive pulmonary disease. Chest. 1989;96(6):1258-62.

Cite this article as: Chauhan P, Chetiwal R. Renin angiotensin system and pulmonary hemodynamics in chronic obstructive pulmonary disease. Int J Adv Med 2018;5:404-8.